Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.

Date publication

avril 2016

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF, Bourdier de Beauregard M, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, Planchard D, Chaput N, Robert C, Carbonnel F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26783344

Résumé

Therapeutic monoclonal anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies are associated with immune-mediated enterocolitis. The aim of this study was to provide a detailed description of this entity.

Mots clés

Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, adverse effects, CTLA-4 Antigen, immunology, Colectomy, Colon, pathology, Enterocolitis, chemically induced, Female, Humans, Immunotherapy, adverse effects, Inflammatory Bowel Diseases, chemically induced, Male, Melanoma, therapy, Middle Aged, Young Adult

Référence

J Crohns Colitis. 2016 Apr;10(4):395-401